ClinicalTrials.gg
TerminatedNCT00643604Updated Jan 3, 2024Results posted

Rapid Switch From Flolan to Remodulin in the Outpatient Clinic

A Phase 4 interventional study of treprostinil sodium in Hypertension, Pulmonary, sponsored by United Therapeutics. Terminated at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-01-03.

Primary conditionPulmonary Arterial HypertensionRegistry: Hypertension, PulmonaryReclassifiedWhy we changed it
Registry
Hypertension, Pulmonary — the first condition term the registry derived for this study.
ClinicalTrials.gg
Pulmonary Arterial Hypertension
Why
  1. The study's title name Pulmonary Arterial Hypertension, a narrower term within Hypertension, Pulmonary.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by United Therapeutics · Phase 4, Interventional, and Treatment

Why this study was terminated
Due to availability of eligible subjects at center and enrollment competition with other studies.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
7
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies testing treprostinil in Pulmonary Arterial Hypertension — 3 open to participants now, 5 under way, 2 of them phase 3. treprostinil · Pulmonary Arterial Hypertension.

Enrollment
36th of 44
7 · median 32
Started
2008
with 3 others
Phase 4
14 of 44
1 open now
Registered
7th of 44
by date
Lead sponsor
32 of 44
United Therapeutics

Among the 44 studies testing treprostinil in Pulmonary Arterial Hypertension, this one is the 36th largest by enrollment, is one of 4 that started in 2008, is one of 14 in phase 4, and was the 7th registered.

Pulmonary Arterial Hypertension

700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

3 of the 44 studies testing treprostinil in Pulmonary Arterial Hypertension are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About treprostinil

treprostinil: first FDA approval 2002 (REMODULIN), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing treprostinil in Pulmonary Arterial Hypertension, or all of them as a file.
02

Study summary

The purpose of this 8-week study is to compare the effects of switching from therapy with epoprostenol or Flolan to IV Remodulin. This study will also assess the effect that changing to Remodulin will have on patient satisfaction with their treatment and impact on quality of life.

Read the detailed description

Pulmonary arterial hypertension (PAH), which is defined as an elevation in pulmonary arterial pressure and pulmonary vascular resistance, is a severe hemodynamic abnormality common to a variety of diseases and syndromes. Elevation in pulmonary arterial pressure causes an increase in right ventricular afterload, impairing right ventricular function and ultimately leading to inactivity and death. The goal of PAH treatment is to lengthen survival time, to ameliorate symptoms of PAH and to improve health related quality of life (HRQOL).

Remodulin® (treprostinil sodium), a stable analogue of prostacyclin, possesses potent pulmonary and systemic vasodilatory and platelet anti-aggregatory actions in vitro and in vivo. Recently, Remodulin received FDA approval for intravenous therapy based upon bioequivalence of the IV and SC routes of administration. Remodulin is more chemically stable than epoprostenol and may offer potential safety and convenience advantages compared to intravenous epoprostenol that may impact Health Related Quality of Life (HRQOL) and/or patient satisfaction. Unlike epoprostenol, Remodulin does not need to be mixed daily and is stable at room temperature eliminating the need for ice packs. Furthermore, since Remodulin remains in the body longer than epoprostenol (4 hrs instead of less than 5 minutes) there is less risk of cardiovascular collapse from a sudden interruption of infusion, such as a line clog. In an open-label study in Europe, patients who were using a type of portable medication pump called the CADD Legacy pump were rapidly switched from Flolan to Remodulin with no serious side effects. This study will examine effects of switching from therapy with epoprostenol or Flolan to IV Remodulin and compare changes in HRQOL and treatment satisfaction before and after rapid switch from epoprostenol to Remodulin in patients with pulmonary hypertension using the CADD legacy pump.

03

Conditions studied

  • Hypertension, Pulmonary

Browse trials for

Keywords

  • Pulmonary arterial hypertension
  • treatment satisfaction
  • rapid switch
  • remodulin
  • Quality of life
04

In context

Pulmonary Arterial Hypertension Reclassified

700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.

This study's enrollment of 7 is below the median of 40 across 478 interventional studies indexed under Pulmonary Arterial Hypertension.

Browse Pulmonary Arterial Hypertension studies →

Lead sponsor

United Therapeutics is the lead sponsor of 85 studies on the registry; 8 are open to participants now.

Of its 17 completed or terminated interventional studies of FDA-regulated products, 15 (88%) have results posted.

Compared within Pulmonary Arterial Hypertension, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hypertension, Pulmonary. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be between 18 years and 70 years of age
  • Be male or if female, be physiologically incapable of childbearing or practicing an acceptable method of (women of must have a negative pregnancy test).
  • Have a current World Health Organization (WHO) functional classification of II-III status
  • Diagnosis of one of the following WHO Classifications of pulmonary hypertension: Group 1 pulmonary arterial hypertension (IPAH, FPAH, APAH);Group 3 pulmonary hypertension associated with lung disease (Mild interstitial lung disease associated with predominant features of right heart failure as seen in Group 1 PAH patients); Group 4 pulmonary hypertension due to chronic thromboembolic pulmonary hypertension (CTEPH)
  • In the opinion of the investigator, be hemodynamically stable with no signs or symptoms of disease progression
  • Be receiving intravenous epoprostenol therapy for at least three months and a stable dose for at least one month prior to Baseline.
  • Have a central intravenous catheter in place.
  • Have a baseline six-minute walk distance of at least 150 meters.
  • Be optimally treated with conventional pulmonary hypertension therapy and clinically stable for at least one month prior to baseline assessments.
  • Be mentally and physically capable of learning to administer Remodulin using an intravenous infusion pump.

Exclusion criteria

Exclusion Criteria:

  • Be a nursing or pregnant woman
  • Have had a new type of chronic therapy (including but not limited to oxygen, a different category of vasodilator, a diuretic, digoxin, bosentan, sildenafil) for pulmonary hypertension added within the last month.
  • Have any PAH medication discontinued within the week prior to study entry.
  • Received any prostacyclin or prostacyclin analog except epoprostenol in the past 3 months.
  • Have an on-going central venous line infection within the past 30 days.
  • Have evidence of predominant left-sided heart disease
  • Have any other disease that is associated with pulmonary hypertension (e.g. sickle cell anemia, schistosomiasis).
  • Have a musculoskeletal disorder (e.g. arthritis, artificial leg, etc.) or any other disease, which is thought to limit ambulation, or be connected to a machine, which is not portable.
  • Have uncontrolled systemic hypertension as evidenced by a systolic blood pressure greater than 160 mmHg or diastolic blood pressure greater than 100 mmHg.
  • Be receiving an drug, have in place an investigational device, or have participated in an investigational drug study within the past 30 days.
  • Have the presence of any physiological or psychological condition that contraindicates the administration of Remodulin.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    treprostinil sodium

    all subjects had switched from IV epoprostenol to IV treprostinil sodium

    Drug: treprostinil sodium

Interventions

  • rapid switch from intravenous epoprostenol on CADD ambulatory pump to intravenous treprostinil sodium

    Also known as: Remodulin, Flolan

07

What researchers measure

Primary outcomes

  1. Change in Six Minute Walk Distance

    Time frame: Baseline and Week 8

Secondary outcomes

  1. Change in WHO Functional Classification

    Class I: No limitation of physical activity. Class II: Slight limitation of physical activity. Class III: Marked limitation of physical activity. Class IV: Inability to carry out any physical activity without symptoms.

    Time frame: Baseline and Week 8

  2. Change in Borg Dyspnea Score Immediately After Six Minute Walk

    The Borg Dyspnea Score is a 10-point scale rating the maximum level of dyspnea experienced after the Six-Minute Walk Test. Scores range from 0 (for the best condition) to 10 (for the worst condition).

    Time frame: Baseline and Week 8

  3. Change in Score on Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR)

    The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR), a validated PAH-specific instrument consisting of 65 items used to assess symptoms, functioning and quality of life. The questionnaire is divided into three sections; Symptoms (Scores 0-25; high scores indicate more symptoms), Activity (Score 0-30; low score indicates good functioning)and Quality of Life (0-25; high scores indicate poor QoL). The sum of these scores equates to the Total score (0-80). In the CAMPHOR scores, lower scores indicate improvements.

    Time frame: Baseline and Week 8

  4. Change in Score on Treatment Satisfaction Questionnaire for Medication

    The Treatment Satisfaction Questionnaire for Medication (TSQM), a validated generic measure of treatment satisfaction consisting of 14 Likert-response items comprising four domains: Effectiveness, Side Effects, Convenience, and Global Satisfaction. The TSQM was completed at baseline and at Week 8. The TSQM consists of 13 items that made up three specific scales (Effectiveness, Side effects, Convenience) and one global satisfaction scale. TSQM items are scaled using either a 5-point or 7-point scale. Five-point scales are used for unidimensional continua (e.g. extremely satisfied to not at all), while 7-point scales are used for bipolar continua(e.g., extremely positive to extremely negative. Non-neutral midpoints are used for 7-point scales, resulting in a greater range of positive response options than negative options for these items. Scale scores are transformed into scores ranging from 0 to 100, with a higher score indicating more satisfaction.

    Time frame: Baseline and Week 8

  5. Change in Total Weekly Time Spent With the Specific Activities Associated With Intravenous Remodulin Therapy Compared to Same Activities With Intravenous Epoprostenol

    A Drug Administration Activities Diary, used by subjects to record in detail the amount of time (in minutes) spent on specifically-defined drug preparation/administration activities (e.g. diluting drug, preparing reservoir, and changing tubing), was completed over a 7-day period during the Screening period while on epoprostenol and repeated at Week 7 following transition to Remodulin. Drug Administration Activities Diary results are reported as average time per week spent on drug administration activities

    Time frame: Baseline and Week 8

  6. Change in PAH Signs and Symptoms- Fatigue

    The presence or absence of fatigue was documented. If present, the intensity of fatigue was rated mild, moderate, or severe.

    Time frame: Baseline and Week 8

  7. Change From in Signs and Symptoms of PAH- Edema

    The presence or absence of edema was documented. If present, the intensity of edema was rated mild, moderate, or severe.

    Time frame: Baseline and Week 8

  8. Change in Signs and Symptoms of PAH- Dyspnea

    The presence or absence of dyspnea was documented. If present, the intensity of dyspnea was rated mild, moderate, or severe.

    Time frame: Baseline and Week 8

  9. Change in Signs and Symptoms of PAH- Orthopnea

    The presence or absence of orthopnea was documented. If present, the intensity of orthopnea was rated mild, moderate, or severe.

    Time frame: Baseline and Week 8

  10. Change in Signs and Symptoms of PAH- Dizziness

    The presence or absence of dizziness was documented. If present, the intensity of dizziness was rated mild, moderate, or severe.

    Time frame: Baseline and Week 8

  11. Change in Signs and Symptoms of PAH- Syncope

    The presence or absence of syncope was documented. If present, the intensity of syncope was rated mild, moderate, or severe.

    Time frame: Baseline and Week 8

  12. Change in Signs and Symptoms of PAH- Chest Pain

    The presence or absence of chest pain was documented. If present, the intensity of chest pain was rated mild, moderate, or severe.

    Time frame: Baseline and Week 8

  13. Patient Impression of Change Questionnaire

    A Patient Global Impression of Change Questionnaire, which consists of three items that ask the subject to rate changes (much better, somewhat better, about the same, somewhat worse, much worse) in their symptoms of PAH, the amount of time spent on activities associated with preparing and administering PAH therapy, and their satisfaction with their PAH therapy since transitioning from epoprostenol to intravenous Remodulin was conducted at Week 8 only and responses are reported as frequency distributions.

    Time frame: Week 8

08

Results

Posted Jun 21, 2013
Limitations and caveats
The main limitations of this study are the small sample size, open-label design and relatively short duration of follow-up.

Participant flow

The first subject was enrolled in March 2008. Given the limited availability of eligible subjects at the investigative center (stable PH patients on stable epoprostenol therapy) and competition for enrollment by other studies, after an extended recruitment period during which no new subjects were enrolled, the study was subsequently closed.

Participant flow — Overall Study
MilestoneTreprostinil Sodium
Started7
Completed6
Not completed1
Withdrew: Death1

Outcome measures

PrimaryChange in Six Minute Walk Distance
Time frame:
Baseline and Week 8
Reported as:
Mean · meter
Change in Six Minute Walk Distance
meterTreprostinil Sodium
Change in Six Minute Walk Distance-14 ± 63.7
Statistical analysis
  • Treprostinil Sodium · Wilcoxon signed-rank test · p = 0.69
SecondaryChange in WHO Functional Classification

Class I: No limitation of physical activity. Class II: Slight limitation of physical activity. Class III: Marked limitation of physical activity. Class IV: Inability to carry out any physical activity without symptoms.

Time frame:
Baseline and Week 8
Reported as:
Number · participants
Change in WHO Functional Classification
participantsTreprostinil Sodium
Improved0
No change5
Worsened1
Statistical analysis
  • Treprostinil Sodium · Wilcoxon signed-rank test · p = 1.00
SecondaryChange in Borg Dyspnea Score Immediately After Six Minute Walk

The Borg Dyspnea Score is a 10-point scale rating the maximum level of dyspnea experienced after the Six-Minute Walk Test. Scores range from 0 (for the best condition) to 10 (for the worst condition).

Time frame:
Baseline and Week 8
Reported as:
Mean · units on a scale
Change in Borg Dyspnea Score Immediately After Six Minute Walk
units on a scaleTreprostinil Sodium
Change in Borg Dyspnea Score Immediately After Six Minute Walk0.67 ± 0.52
Statistical analysis
  • Treprostinil Sodium · Wilcoxon signed-rank test · p = 0.13
SecondaryChange in Score on Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR)

The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR), a validated PAH-specific instrument consisting of 65 items used to assess symptoms, functioning and quality of life. The questionnaire is divided into three sections; Symptoms (Scores 0-25; high scores indicate more symptoms), Activity (Score 0-30; low score indicates good functioning)and Quality of Life (0-25; high scores indicate poor QoL). The sum of these scores equates to the Total score (0-80). In the CAMPHOR scores, lower scores indicate improvements.

Time frame:
Baseline and Week 8
Reported as:
Mean · units on a scale
Change in Score on Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR)
units on a scaleTreprostinil Sodium
Symptom Score-2.5 ± 2.0
Activitity Score-0.8 ± 2.6
Quality of Life Score-4.4 ± 6.7
Total Score-8.0 ± 8.9
Statistical analysis
  • Treprostinil Sodium · Wilcoxon signed rank test · p = 0.03 (p value for Symptom Score)
  • Treprostinil Sodium · Wilcoxon signed rank test · p = 1.00 (p value for Activity Score.)
  • Treprostinil Sodium · Wilcoxon signed-rank test · p = 0.31
  • Treprostinil Sodium · Wilcoxon signed-rank test · p = 0.13
SecondaryChange in Score on Treatment Satisfaction Questionnaire for Medication

The Treatment Satisfaction Questionnaire for Medication (TSQM), a validated generic measure of treatment satisfaction consisting of 14 Likert-response items comprising four domains: Effectiveness, Side Effects, Convenience, and Global Satisfaction. The TSQM was completed at baseline and at Week 8. The TSQM consists of 13 items that made up three specific scales (Effectiveness, Side effects, Convenience) and one global satisfaction scale. TSQM items are scaled using either a 5-point or 7-point scale. Five-point scales are used for unidimensional continua (e.g. extremely satisfied to not at all), while 7-point scales are used for bipolar continua(e.g., extremely positive to extremely negative. Non-neutral midpoints are used for 7-point scales, resulting in a greater range of positive response options than negative options for these items. Scale scores are transformed into scores ranging from 0 to 100, with a higher score indicating more satisfaction.

Time frame:
Baseline and Week 8
Reported as:
Mean · units on a scale
Change in Score on Treatment Satisfaction Questionnaire for Medication
units on a scaleTreprostinil Sodium
Effectiveness Score-9.3 ± 13.0
Side-Effects Score19.8 ± 28.9
Convenience Score22.2 ± 12.2
Global Satisfaction Score-1.2 ± 21.4
Statistical analysis
  • Treprostinil Sodium · Wilcoxon signed-rank test · p = 0.19
  • Treprostinil Sodium · Wilcoxon signed-rank test · p = 0.19
  • Treprostinil Sodium · Wilcoxon signed-rank test · p = 0.03
  • Treprostinil Sodium · Wilcoxon signed-rank test · p = 0.88
SecondaryChange in Total Weekly Time Spent With the Specific Activities Associated With Intravenous Remodulin Therapy Compared to Same Activities With Intravenous Epoprostenol

A Drug Administration Activities Diary, used by subjects to record in detail the amount of time (in minutes) spent on specifically-defined drug preparation/administration activities (e.g. diluting drug, preparing reservoir, and changing tubing), was completed over a 7-day period during the Screening period while on epoprostenol and repeated at Week 7 following transition to Remodulin. Drug Administration Activities Diary results are reported as average time per week spent on drug administration activities

Time frame:
Baseline and Week 8
Reported as:
Mean · minutes
Change in Total Weekly Time Spent With the Specific Activities Associated With Intravenous Remodulin Therapy Compared to Same Activities With Intravenous Epoprostenol
minutesTreprostinil Sodium
Gather/Set-up-2.6 ± 4.0
Prepare Drug-39.4 ± 12.8
Connect Drug-5.0 ± 11.3
Change Dressing0.0 ± 10.6
Total Time-44.0 ± 25.2
Statistical analysis
  • Treprostinil Sodium · Wilcoxon signed-rank test · p = 0.25
  • Treprostinil Sodium · Wilcoxon signed-rank test · p = 0.06
  • Treprostinil Sodium · Wilcoxon signed-rank test · p = 0.63
  • Treprostinil Sodium · Wilcoxon signed-rank test · p = 0.88
  • Treprostinil Sodium · Wilcoxon signed-rank test · p = 0.13
SecondaryChange in PAH Signs and Symptoms- Fatigue

The presence or absence of fatigue was documented. If present, the intensity of fatigue was rated mild, moderate, or severe.

Time frame:
Baseline and Week 8
Reported as:
Number · participants
Change in PAH Signs and Symptoms- Fatigue
participantsTreprostinil Sodium
Improved0
No Change4
Worsened2
Statistical analysis
  • Treprostinil Sodium · Wilcoxon signed-rank test · p = 0.5
SecondaryChange From in Signs and Symptoms of PAH- Edema

The presence or absence of edema was documented. If present, the intensity of edema was rated mild, moderate, or severe.

Time frame:
Baseline and Week 8
Reported as:
Number · participants
Change From in Signs and Symptoms of PAH- Edema
participantsTreprostinil Sodium
Improved0
No Change3
Worsened3
Statistical analysis
  • Treprostinil Sodium · Wilcoxon sign-rank test · p = 0.25
SecondaryChange in Signs and Symptoms of PAH- Dyspnea

The presence or absence of dyspnea was documented. If present, the intensity of dyspnea was rated mild, moderate, or severe.

Time frame:
Baseline and Week 8
Reported as:
Number · participants
Change in Signs and Symptoms of PAH- Dyspnea
participantsTreprostinil Sodium
Improved1
No Change3
Worsened2
Statistical analysis
  • Treprostinil Sodium · Wilcoxon signed-rank test · p = 1.00
SecondaryChange in Signs and Symptoms of PAH- Orthopnea

The presence or absence of orthopnea was documented. If present, the intensity of orthopnea was rated mild, moderate, or severe.

Time frame:
Baseline and Week 8
Reported as:
Number · participants
Change in Signs and Symptoms of PAH- Orthopnea
participantsTreprostinil Sodium
Improved0
No Change4
Worsened2
Statistical analysis
  • Treprostinil Sodium · Wilcoxon signed-rank test · p = 0.50
SecondaryChange in Signs and Symptoms of PAH- Dizziness

The presence or absence of dizziness was documented. If present, the intensity of dizziness was rated mild, moderate, or severe.

Time frame:
Baseline and Week 8
Reported as:
Number · participants
Change in Signs and Symptoms of PAH- Dizziness
participantsTreprostinil Sodium
Improved0
No Change5
Worsened1
Statistical analysis
  • Treprostinil Sodium · Wilcoxon signed-rank test · p = 1.00
SecondaryChange in Signs and Symptoms of PAH- Syncope

The presence or absence of syncope was documented. If present, the intensity of syncope was rated mild, moderate, or severe.

Time frame:
Baseline and Week 8
Reported as:
Number · participants
Change in Signs and Symptoms of PAH- Syncope
participantsTreprostinil Sodium
Improved0
No Change6
Worsened0
Statistical analysis
  • Treprostinil Sodium · Wilcoxon signed-rank test · p = 1.00
SecondaryChange in Signs and Symptoms of PAH- Chest Pain

The presence or absence of chest pain was documented. If present, the intensity of chest pain was rated mild, moderate, or severe.

Time frame:
Baseline and Week 8
Reported as:
Number · participants
Change in Signs and Symptoms of PAH- Chest Pain
participantsTreprostinil Sodium
Improved0
No Change5
Worsened1
Statistical analysis
  • Treprostinil Sodium · Wilcoxon signed-rank test · p = 1.00
SecondaryPatient Impression of Change Questionnaire

A Patient Global Impression of Change Questionnaire, which consists of three items that ask the subject to rate changes (much better, somewhat better, about the same, somewhat worse, much worse) in their symptoms of PAH, the amount of time spent on activities associated with preparing and administering PAH therapy, and their satisfaction with their PAH therapy since transitioning from epoprostenol to intravenous Remodulin was conducted at Week 8 only and responses are reported as frequency distributions.

Time frame:
Week 8
Reported as:
Number · participants
Patient Impression of Change Questionnaire
participantsTreprostinil Sodium
Symptoms- Much Better0
Symptoms-Somewhat Better2
Symptoms- About the Same3
Symptoms- Somewhat Worse1
Symptoms-Much Worse0
Time Spent- Much Less3
Time Spent- Somewhat Less3
Time Spent- About the Same0
Time Spent- Somewhat More0
Time Spent- Much More0
Satisfaction- Much More Satisfied1
Satisfaction- More Satisfied3
Satisfaction- About the Same1
Satisfaction- Less Satisfied1
Satisfaction- Much Less Satisfied0

Adverse events

Collected over Adverse events were assessed upon initiation of Remodulin through to the end of study (Week 8). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treprostinil Sodium—2/7 (28.6%)6/7 (85.7%)
Most frequent serious events
Most frequent serious events
EventTreprostinil Sodium
Abdominal painGastrointestinal disorders1/7
BacteraemiaInfections and infestations1/7
DehydrationMetabolism and nutrition disorders1/7
NauseaGastrointestinal disorders1/7
VomitingGastrointestinal disorders1/7
Most frequent other events
Showing 10 of 18
Most frequent other events
EventTreprostinil Sodium
HeadacheNervous system disorders5/7
NauseaGastrointestinal disorders3/7
VomitingGastrointestinal disorders3/7
DiarrhoeaGastrointestinal disorders3/7
Pain in ExtremityMusculoskeletal and connective tissue disorders3/7
AnxietyPsychiatric disorders2/7
InsomniaPsychiatric disorders2/7
ArthralgiaMusculoskeletal and connective tissue disorders1/7
Back PainMusculoskeletal and connective tissue disorders1/7
CoughRespiratory, thoracic and mediastinal disorders1/7

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Treprostinil Sodium
<=18 years0
Between 18 and 65 years7
>=65 years0
Age, Continuous
Age, Continuous(years)Treprostinil Sodium
Mean43.6 ± 32-58
Sex: Female, Male
Sex: Female, Male(Participants)Treprostinil Sodium
Female5
Male2
Region of Enrollment
Region of Enrollment(participants)Treprostinil Sodium
United States7
Pulmonary Arterial Hypertension (PAH) etiology
Pulmonary Arterial Hypertension (PAH) etiology(participants)Treprostinil Sodium
Idiopathic PAH5
Collagen Vascular Disease1
Portal Hypertension1
World Health Organization (WHO) functional Class at time of transition
World Health Organization (WHO) functional Class at time of transition(participants)Treprostinil Sodium
Class II5
Class III2
Baseline 6 Minute Walk Distance (6MWD)
Baseline 6 Minute Walk Distance (6MWD)(meters)Treprostinil Sodium
Mean466.6 (343 to 565)
09

Study locations

1 site
  • Duke University Medical Center
    Durham, North Carolina 27705, United States
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2008, a primary completion of Jan 2010 and a completion of Feb 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2013, 3 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2008
First posted
Mar 26, 2008
Start
Mar 2008
Primary completionActual
Jan 2010
CompletionActual
Feb 2012
Results first posted
Jun 21, 2013
Last update
Jan 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00643604
Responsible party
Sponsor
First posted
Mar 26, 2008
Start date
Mar 2008
Primary completion
Jan 2010
Completion
Feb 2012
Results posted
Jun 21, 2013
Last update
Jan 3, 2024

Study contacts

Victor Tapson, MD
principal investigator · Duke Health

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Treprostinil

Start the discussion